Neoprobe achieves accrual goal in Lymphoseek Phase 3 study in breast cancer/melanoma
 

Neoprobe Corporation, a diversified developer of innovative oncology surgical and diagnostic products, today announced that a multi-center Phase 3 study of Lymphoseek® has enrolled clinical subjects to achieve the minimum analysis goal of 196 lymph nodes, the study's primary accrual objective.

More...